103 related articles for article (PubMed ID: 2549731)
1. [Tumor markers in bronchus cancer].
Gasser RW; Denz H; Huber H
Wien Klin Wochenschr; 1989 Jul; 101(14):476-9. PubMed ID: 2549731
[TBL] [Abstract][Full Text] [Related]
2. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
3. [Neuron-specific enolase as a tumor marker in small cell bronchial carcinoma].
Gasser RW; Herold M; Müller-Holzner E; Müller LC; Salzer GM; Huber H
Dtsch Med Wochenschr; 1988 Nov; 113(44):1708-13. PubMed ID: 2846253
[TBL] [Abstract][Full Text] [Related]
4. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
5. [Diagnostic significance of the tumor markers CEA, SCC and NSE in serum and bronchoalveolar lavage].
von Eiff M; Koch O; Appelhans N; Roos N; van de Loo J
Pneumologie; 1990 Feb; 44 Suppl 1():462-4. PubMed ID: 2164198
[TBL] [Abstract][Full Text] [Related]
6. [Importance of serum TPA determination in bronchopulmonary cancer. A comparative study of CEA, CA 19.9 and NSE].
Prévost A; Passemard F; Perdu D; Vallerand H; Deschamps F; Lavaud F; Larbre H
Rev Mal Respir; 1994; 11(4):379-84. PubMed ID: 7973038
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of tumor markers in lung biopsies and in bronchial lavage].
Vogel J; Loos U; Oehr P
Pneumologie; 1990 Feb; 44 Suppl 1():465-6. PubMed ID: 2164199
[TBL] [Abstract][Full Text] [Related]
8. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
Schneider J; Philipp M; Salewski L; Velcovsky HG
Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
[TBL] [Abstract][Full Text] [Related]
9. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
Ebert W; Muley T; Drings P
Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
[TBL] [Abstract][Full Text] [Related]
10. [Determination of various tumor markers, with special reference to neuron-specific enolase in lung cancer].
Yano H; Hino M; Nishiwaki Y; Kodama T; Hayashibe A; Kudo H; Inoue Y; Nishiyama Y; Sone Y; Oshima T
Gan To Kagaku Ryoho; 1987 Jan; 14(1):77-83. PubMed ID: 3026257
[TBL] [Abstract][Full Text] [Related]
11. Expression of CEA and trophoblastic cell markers by lung carcinoma in association with histological characteristics and serum marker levels.
Slodkowska J; Szturmowicz M; Rudzinski P; Giedronowicz D; Sakowicz A; Androsiuk W; Zakrzewska-Rowinska E
Eur J Cancer Prev; 1998 Feb; 7(1):51-60. PubMed ID: 9511851
[TBL] [Abstract][Full Text] [Related]
12. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
13. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Philipp M; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Clin Exp Med; 2003 Feb; 2(4):185-91. PubMed ID: 12624710
[TBL] [Abstract][Full Text] [Related]
14. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
[TBL] [Abstract][Full Text] [Related]
15. [Tumor markers, significance for clinical diagnosis].
Gropp C
Pneumologie; 1991 Apr; 45(4):137-9. PubMed ID: 1876589
[TBL] [Abstract][Full Text] [Related]
16. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
17. [Creatine kinase BB and neuron specific r-enolase as biomarkers for lung cancer].
Usui A; Fujita K; Imaizumi M; Abe T; Inoue K; Matsumoto S; Kato K
Gan No Rinsho; 1987 Nov; 33(14):1763-70. PubMed ID: 2826840
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer.
Graziano SL; Tatum AH; Newman NB; Oler A; Kohman LJ; Veit LJ; Gamble GP; Coleman MJ; Barmada S; O'Lear S
Cancer Res; 1994 Jun; 54(11):2908-13. PubMed ID: 8187076
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
